Does a rifamycin-containing preventive regimen increase rifampicin resistance? An unresolved concern

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 8, 2016, Pages 998-

  Wang, Jann Yuan ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; COST EFFECTIVENESS ANALYSIS; DIRECTLY OBSERVED THERAPY; DRUG MONITORING; DRUG RESISTANT TUBERCULOSIS; EDITORIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; LATENT TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SAMPLE SIZE; SCREENING TEST; THORAX RADIOGRAPHY; TUBERCULOSIS CONTROL;

EID: 84978215439     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0424     Document Type: Editorial

References (5)

1. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection.N Engl JMed 2011; 365: 2155-2166.
2. den Boon S, Alberto M, Getahun H. Rifampicin resistance after treatment for latent tuberculosis infection: A systematic review and meta-analysis. Int JTuberc Lung Dis 2016; 20: 1065-1071.
3. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J2015; 46: 1563-1576.
4. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. NEngl JMed 1994; 330: 1179-1184.
5. Weiner M, Savic RM, Kenzie WR, et al. Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection. JPediatric Infect Dis Soc 2014; 3: 132-145.